Adverum Biotechnologies Inc (NASDAQ:ADVM) on Focus After Report of More Shorts

The stock of Adverum Biotechnologies Inc (NASDAQ:ADVM) registered an increase of 26.96% in short interest. ADVM’s total short interest was 2.51 million shares in July as published by FINRA. Its up 26.96% from 1.97 million shares, reported previously. With 233,600 shares average volume, it will take short sellers 11 days to cover their ADVM’s short positions.

The stock decreased 2.48% or $0.38 during the last trading session, reaching $14.97. About 931,531 shares traded or 8.98% up from the average. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has risen 7.50% since July 14, 2018 and is uptrending. It has outperformed by 3.07% the S&P500.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $954.80 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

More notable recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: which released: “Adverum Biotechnologies (ADVM) Upgraded to Buy: What Does It Mean for the Stock? – Nasdaq” on March 12, 2019, also with their article: “Here’s What Hedge Funds Think About Daktronics, Inc. (DAKT) – Yahoo Finance” published on June 28, 2019, published: “Adverum Biotechnologies (ADVM) Presents At 37th Annual J.P. Morgan Healthcare Conference – Slideshow – Seeking Alpha” on January 10, 2019. More interesting news about Adverum Biotechnologies, Inc. (NASDAQ:ADVM) were released by: and their article: “The Daily Biotech Pulse: Inovio’s Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation – Benzinga” published on May 29, 2019 as well as‘s news article titled: “Adverum: Assessing The Strong Prospects Of A Gene Therapy Innovator – Seeking Alpha” with publication date: May 23, 2018.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.